TrialBMC medicine2025

Camrelizumab and apatinib in Chinese patients with locally advanced or metastatic radioiodine-refractory differentiated thyroid cancer: an exploratory open-label, single-arm trial.

Xin Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.